Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Phamraceuticals LtdfiledCriticalActelion Phamraceuticals Ltd
Publication of CL2009000621A1publicationCriticalpatent/CL2009000621A1/en
CL2009000621A2008-03-172009-03-16 Use of a selective s1p1 receptor agonist to prepare a medicament useful in the treatment of diseases or disorders associated with an activated immune system.CL2009000621A1 (en)
Use of a selective s1p1 receptor agonist to prepare a medicament useful in the treatment of diseases or disorders associated with an activated immune system.
Use of an alpha-7 nicotinic acetylcholine receptor agonist for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.
preparation comprising at least one chemotherapeutic or cytotoxic substance for use in treating a mammalian patient's disease, preparation and method for treating cancer in a mammalian patient by radiation therapy
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
Compounds derived from benzoxazepine condensed with pyrazolyl or imidazolyl, inhibitors of pi3 kinase activity; pharmaceutical composition comprising a compound; and its use in the preparation of drugs for the treatment of cancer.
Use of a combination of at least one chemotherapeutic agent and an effective amount of an anti-vegf antibody (vascular endothelial growth factor), because it serves to prepare a medicament useful in the treatment of ovarian cancer; and his kit to treat ovarian cancer without prior treatment in a human patient.